New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for ...

Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or ...

The selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.

US biotech Vima Therapeutics has secured $40 million in a series A extension to support development of its oral movement-disorder therapy VIM0423, bringing the total financing round to $100 million.

Add Yahoo as a preferred source to see more of our stories on Google. When we think of movement disorders, the tremors associated with Parkinson’s disease are probably what first spring to mind.

An artificial intelligence tool called DystoniaBoTXNet predicted which patients with dystonia would benefit from botulinum toxin injections with 96.3% accuracy. DystoniaBoTXNet could be a tool to aid ...

(WTNH) — There are an estimated 300,000 Americans who have been diagnosed with dystonia, and yet, not many people say they’ve heard about it. Dystonia is a movement disorder that causes the muscles to ...

MICKLETON, N.J. (WPVI) -- Nearly everyone gets a muscle cramp from time to time. When muscle contractions won't stop and can't be controlled, that's called dystonia. A South Jersey man is now sharing ...

Oct. 14 (UPI) --A new award will help early career researchers who study dystonia, the Michael J. Fox Foundation announced Tuesday. The new Bachmann-Strauss Early Career Award is a two-year, $150,000 ...

Jonathan Allen first picked up the trombone in the fourth grade. After playing for years, he eventually earned a doctorate in musical arts and a teaching position at the University of Iowa. Then, one ...